Acute myeloid leukemia is the most common type of acute leukemia in adults. The "3+7" regimen composed of anthracyclines and cytarabine has been established as the standard induction regimen for AML patients since the 70s of the 20th centuries. Since then, clinical studies have been conducted to improve and optimize the first-line induction regimen, and to investigate whether the new regimen has more advantages in terms of efficacy and safety than the standard induction regimen. This article mainly describes the progress of first-line induction therapy regimens for AML, and the research of related molecular targeted drugs, so as to provide reference for clinical treatment.